Y
Yang Feng
Researcher at University of Florida
Publications - 10
Citations - 49
Yang Feng is an academic researcher from University of Florida. The author has contributed to research in topics: DNA damage & Medicine. The author has an hindex of 2, co-authored 6 publications receiving 12 citations.
Papers
More filters
Journal ArticleDOI
HOXBLINC long non-coding RNA activation promotes leukemogenesis in NPM1-mutant acute myeloid leukemia
Ganqian Zhu,Huacheng Luo,Yang Feng,Olga A. Guryanova,Jianfeng Xu,Shi Chen,Shi Chen,Qian Lai,Arati Sharma,Bing Xu,Zhigang Zhao,Ru Feng,Hongyu Ni,David F. Claxton,David F. Claxton,Ying Guo,Ruben A. Mesa,Yi Qiu,Feng Chun Yang,Wei Li,Stephen D. Nimer,Suming Huang,Suming Huang,Mingjiang Xu +23 more
TL;DR: In this article, the activation of HOXBLINC, a HOXB locus-associated long non-coding RNA (lncRNA), is shown to be a critical downstream mediator of NPM1c+-associated leukemic transcription program and leukemogenesis.
Journal ArticleDOI
Alterations to DNMT3A in Hematologic Malignancies.
TL;DR: Recent advances in understanding of the biochemical and structural consequences of DNMT3A mutations on DNA methylation catalysis and binding interactions are discussed and their effects on epigenetic patterns and gene expression changes implicated in the pathogenesis of hematologic malignancies are summarized.
Journal ArticleDOI
T-cell exhaustion in immune-mediated inflammatory diseases: New implications for immunotherapy
TL;DR: This review will focus on the research progress of T-cell exhaustion in several IMIDs and its potential application for diagnosis and treatment in IMIDs.
Journal ArticleDOI
Combination strategies to promote sensitivity to cytarabine-induced replication stress in acute myeloid leukemia with and without DNMT3A mutations.
TL;DR: Venugopal et al. as discussed by the authors discussed PARP inhibition as a rational strategy to increase cytarabine efficacy in cells without DNMT3A mutations, while considering the implications of PARP inhibitor resistance for promoting clonal hematopoiesis.
Posted ContentDOI
DNMT3A harboring leukemia-associated mutations directs sensitivity to DNA damage at replication forks
Kartika Venugopal,Pawel Nowialis,Yang Feng,Daniil Shabashvili,Cassandra M. Berntsen,Kathryn I. Krajcik,C. Taragjini,Zachary Zaroogian,H. L. Casellas-Roman,Luisa M Posada,Chamara Gunaratne,Jennifer W Li,Daphné Dupéré-Richer,Richard L. Bennett,Richard L. Bennett,Santhi Pondugula,Alberto Riva,Alberto Riva,Christopher R. Cogle,Christopher R. Cogle,Rene Opavsky,Rene Opavsky,Brian K. Law,Brian K. Law,Stefan Kubicek,Philipp B. Staber,Jonathan D. Licht,Jonathan D. Licht,Jonathan E. Bird,Olga A. Guryanova,Olga A. Guryanova +30 more
TL;DR: In this article, pharmacologically-induced replication fork stalling creates a therapeutic vulnerability in cells with DNMT3A(R882) mutations, which is associated with resistance to standard chemotherapy, disease relapse, and poor prognosis.